Latest News and Events
Filter by
Selections
October 8, 2020
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Read MoreSeptember 30, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
Read MoreSeptember 24, 2020
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreSeptember 16, 2020
Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
Read MoreSeptember 8, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
Read MoreAugust 31, 2020
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
Read MoreAugust 28, 2020